Palvella Therapeutics (PVLA) to Release Quarterly Earnings on Thursday

Palvella Therapeutics (NASDAQ:PVLA) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Thursday, August 14th. Analysts expect Palvella Therapeutics to post earnings of ($0.81) per share for the quarter.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share for the quarter, beating the consensus estimate of ($3.40) by $2.66. On average, analysts expect Palvella Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Palvella Therapeutics Stock Up 3.6%

NASDAQ:PVLA opened at $43.21 on Wednesday. The stock’s 50-day simple moving average is $29.20 and its 200 day simple moving average is $24.72. The firm has a market capitalization of $477.90 million, a PE ratio of -3.57 and a beta of -0.01. Palvella Therapeutics has a twelve month low of $11.17 and a twelve month high of $44.04.

Hedge Funds Weigh In On Palvella Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Rhumbline Advisers acquired a new position in shares of Palvella Therapeutics in the second quarter worth approximately $224,000. JPMorgan Chase & Co. lifted its stake in shares of Palvella Therapeutics by 108,066.7% in the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after acquiring an additional 3,242 shares during the period. Geode Capital Management LLC lifted its stake in shares of Palvella Therapeutics by 84.7% in the second quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after acquiring an additional 79,787 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of Palvella Therapeutics in the first quarter worth approximately $533,000. Finally, Millennium Management LLC acquired a new position in shares of Palvella Therapeutics in the first quarter worth approximately $7,553,000. 40.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Raymond James Financial set a $54.00 price objective on Palvella Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, August 5th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, April 30th. Lifesci Capital initiated coverage on Palvella Therapeutics in a research note on Monday, August 4th. They set an “outperform” rating and a $90.00 price target on the stock. Canaccord Genuity Group cut their price target on Palvella Therapeutics from $53.00 to $52.00 and set a “buy” rating on the stock in a research note on Friday, May 16th. Finally, Truist Financial initiated coverage on Palvella Therapeutics in a research note on Monday, July 21st. They set a “buy” rating and a $56.00 price target on the stock. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $52.40.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.